Conference Day One

Wednesday 22nd May, 2019

8.00          Chair’s Opening Remarks

The Future for Neurodegenerative Drug Development

8.15

Reviewing Past Failures & Challenging Traditional Thinking to Guide Future Research

  • Evaluating why many promising preclinical candidates have failed in neuroprotective clinical trials
  • Discussing the lack of effective biochemical & imaging biomarkers, relatively poor clinical evaluation scales, and limited understanding of patient subgroups
  • Presenting a brighter future, both in conventional and regenerative approaches
  • Reviewing multiple recent breakthroughs in genetics, patient stratification, wearables, AI, and some evolving new clinical successes, now mean that many diverse and promising therapeutic targets will be studied in upcoming clinical trials

Richard Wyse
Global Director of Research and Development
The Cure Parkinson’s Trust

8.45

Moving Forward: The Changing Landscape of Neurodegenerative Drug Discovery & Development

  • Evaluating what ingredients are needed for successful R&D in neurodegenerative disease?
  • Is it possible to build a feasible drug discovery portfolio in neurodegenerative disease in 2019?
  • Predicting the future is not possible, what can we do to model 2025 and beyond?

Ross Jeggo
Head of Research, Neuropsychiatry Center for Therapeutic Innovation
Servier

9.15

Panel Discussion: Future Thinking for Neurodegenerative Disease Drug Development

  • Reviewing the past failures in the neurodegenerative field
  • Evaluating the potential for neurodegenerative drug development • Discussing the lessons learned and future opportunities
  • Encouraging productive and precompetitive behaviours
Ross Jeggo Image

Ross Jeggo
Head of Research, Neuropsychiatry Center for Therapeutic Innovation
Servier

Richard Wyse Image

Richard Wyse
Global Director of Research and Development
The Cure Parkinson’s Trust

9.45 Speed Networking

This session is the ideal opportunity to meet face-to-face with the key thought leaders working in the CNS field. Specifically designed to connect you with new contacts from the most active companies in the field, the renowned Speed Networking session will be one of the most valuable hours you will spend at NDD Europe.

10.30 Morning Refreshments

Seeking Robust Biomarkers of Neurodegeneration & Strategies to Improve Their Translatability

11.00

Linking CSF-Tau Biomarker Changes to Neuropathological Changes in Alzheimer’s Disease

  • Reviewing hyperphosphorylated tau, a key pathological species in Alzheimer’s disease
  • Targeting this species in preclinical models prevents the seeding and spreading of tau pathology
  • Identification of c-terminal tau assays has been a key roadblock in moving tau therapies forward. Here, we present the development of such assays and their evaluation in human and animal samples

Jan Torleif Pedersen
Director, Therapeutic Biology Lead, Alzheimer’s Disease & Dementia, Neuroscience
Lundbeck

11.30

PET Imaging Methods for Intervention Trials in Alzheimer’s Disease: Promises & Pitfalls

  • Tau PET imaging: where do we stand?
  • Identifying the challenges and strengths in quantitative analysis of imaging
    methods
  • Assessing the potential for new markers for tau and functional (PET) imaging
  • PET in AD trials: applying the ATN System
  • Reviewing intervention trials as collaborative research: AMYPAD and EPAD

Mark Schmidt
Senior Director
Janssen

12.00

Roundtable Discussion: Discussing Current Biomarkers of Neurodegeneration & the Advances & Strategies Needed for Future Success in Patient Stratification, Diagnosis & Treatment

  • With the success of neurodegenerative therapeutics relying on the translatability of biomarkers, this discussion will enable you to share your opinions on this topic, including:
Round Table Discussions Image

12.30 Lunch & Networking

Encouraging Precompetitive Strategies, Collaborations & Consortia to Advance the Neurodegenerative Field

2.00

Meeting the Challenges of Neuroscience Drug Discovery Through Open Innovation Collaborations

  • Creating outcome focused, win-win collaborations with academic partners
  • Adapting to the needs of collaborative partners
  • The Therapeutic Innovation Group; a novel collaborative model

Andy Takle
Executive Director & Head, Hatfield Research Laboratories, Neurology Business Group
Eisai

2.30

IMI for Neurodegenerative Disorders: A Public-Private Partnership to Accelerate Drug Discovery

  • Discussing how precompetitive strategies can enable drug discovery
  • Identifying collaborations to advance drug discovery from disease biology on novel target to clinical trial analysis and cohorts
  • Reviewing the success of various IMI projects

Jan Egebjerg Jensen
Senior Director, Neurodegeneration Discovery Biology
Janssen

3.00 Afternoon Refreshments & Networking

3.30

LRRK2: Integrating Collaborative Breakthrough Science with Drug Discovery & Development

  • Leucine rich repeat kinase 2 (LRRK2) is a leading example of how clinical genetic based drug target identification is stimulating a precision medicine-based approach to discovery of disease modifying medicines for people with Parkinson’s
  • Sustained collaborative efforts across academic, charitable and commercial sectors to expedite progress on scientific knowledge of this previously unexplored protein kinase underpin this potentially transformational path to novel treatments
  • How this precompetitive collaborative work has been of fundamental value in translational efforts to identify LRRK2 modulators, evaluate on-target liability risks and enable biomarker assay development & clinical trial design

Alastair D. Reith
Senior Director, External Innovation
GSK

4.00

Panel Discussion: Precompetitive Strategies to Strengthen Neurodegenerative Research

  • Understanding the importance of sharing experiences and pooling data
  • Improving the reproducibility of studies amongst different research groups
  • Discussing alternative funding strategies
Carol Routledge Director of Research Alzheimer’s Research UK

Carol Routledge
Director of Research
Alzheimer’s Research UK

Alastair D. Reith Senior Director, External Innovation GSK

Alastair D. Reith
Senior Director, External Innovation
GSK

Andy Takle Executive Director & Head, Hatfield Research Laboratories, Neurology Business Group Eisai

Andy Takle
Executive Director & Head,
Hatfield Research Laboratories,
Neurology Business Group
Eisai

Hugh Marston Senior Research Fellow & Head of Translational Neuroscience Eli Lilly

Hugh Marston
Senior Research Fellow & Head of Translational Neuroscience
Eli Lilly

4.30 Chair’s Closing Remarks

4.45 Scientific Poster Session

The learning at networking continues at the Poster Session, an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new, beneficial relationships. You will have the opportunity to present and review presentations displaying new data from neurodegenerative disease research, such as novel therapeutic targets and advances in clinical development.